Recent 8-K filings for KAPA

• March 2, 2026, 6:59 PM ET M&A materiality 0.80 positive item 1.01item 8.01item 9.01 ◈ Material Agreements

  Kairos Pharma acquires exclusive worldwide rights to CL-273 from Celyn Therapeutics

  Acquired 100% worldwide rights to CL-273, a pan-EGFR inhibitor for EGFR-mutant NSCLC, from Celyn Therapeutics (backed by OrbiMed and Torrey Pines).

• October 7, 2025, 7:59 PM ET other material materiality 0.70 positive item 1.01item 8.01item 9.01

  Kairos Pharma to Present Phase 2 Prostate Cancer Data at ESMO 2025

  On October 7, 2025, Kairos issued press release announcing ESMO Congress presentation in Berlin from October 17-21.

• September 18, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Kairos Pharma reports positive Phase 2 interim efficacy for ENV105 in mCRPC; median PFS >13 months

  Median PFS >13 months in 8 evaluable patients with mCRPC who failed prior hormone therapy.

• September 11, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Kairos Pharma to host KOL event Sept 18 for ENV105 Phase 2 interim efficacy data

  Virtual KOL event on Sept 18, 2025, at 5 p.m. ET to discuss interim efficacy results from ENV105 Phase 2 trial in advanced prostate cancer.

• July 15, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Kairos Pharma reports positive safety results from Phase 2 ENV-105 trial in mCRPC

  No dose-limiting toxicities or unexpected adverse events in first 10 patients.

• June 3, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Kairos Pharma presents KROS101 preclinical data at ASCO; shows superiority over TRX518

  KROS101 is a small molecule GITR ligand agonist with dual mechanisms: promotes T effector proliferation and reduces T reg suppression.

• January 17, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01

  Kairos Pharma closes $3.5M PIPE offering of pre-funded units and warrants

  Sold 2,500,000 Pre-Funded Units at $1.399/unit, raising gross proceeds of $3,497,500.

• January 14, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01

  Kairos Pharma raises $3.5M in PIPE offering at $1.40/unit with warrants

  Raises $3.5M gross from sale of units at $1.40/Common Unit and $1.399/Pre-Funded Unit.

• September 24, 2024, 7:59 PM ET other material materiality 0.60 positive item 1.01item 8.01item 9.01

  Kairos Pharma enters $900K biomarker agreement with PreCheck for ENV105 trials

  Agreement with PreCheck Health Services for biomarker screening in ongoing lung (NCT05401110) and prostate (NCT05534646) cancer trials.

• September 17, 2024, 7:59 PM ET other material materiality 0.80 positive item 1.01item 7.01item 9.01

  Kairos Pharma closes $6.2M IPO; shares trade on NYSE American under KAPA

  Closed IPO of 1,550,000 shares at $4.00/share; gross proceeds $6,200,000.

Materiality & sentiment trend

Max materiality 0.80 · Median 0.55 · Most common event other_material

12 positive 0 negative 13 neutral

source · KAPA on sec.gov